MedTrace Logo

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

NCT01949935 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 974

Last updated 2013-09-25

No results posted yet for this study

Summary

The hypothesis is that application of Mupirocin to the nose before and after coronary artery bypass grafting surgery will reduce the incidence of surgical site infections.

Conditions

  • Surgical Site Infections

Interventions

DRUG

Mupirocin

Sponsors & Collaborators

  • Horizon Health Network

    lead OTHER

Principal Investigators

  • Craig D Brown, BSc (Med), MD, FRCSC, FACS · New Brunswick Heart Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01949935 on ClinicalTrials.gov